VERX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VERX is not a good buy right now. Price action and trend signals remain bearish (downtrend structure with negative momentum), insiders are aggressively selling, and the latest guidance-related analyst revisions show the Street is still de-risking the story. With no Intellectia buy signals active and options flow skewed heavily to puts on volume, the near-term path of least resistance looks lower. If you want to take action now (and not wait for a cleaner setup), the better decision is to stay out / exit rather than buy.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is deteriorating: MACD histogram is negative (-0.0493) and expanding to the downside. RSI(6) at ~33 is near oversold but not showing a clear reversal signal—so it can stay weak. Key levels: Pivot 19.089 is overhead; near-term resistance at 19.763 (R1) then 20.18 (R2). Support sits at 18.415 (S1) then 17.998 (S2). With the stock closing ~18.91 (and option ref price ~18.55), it’s trading below the pivot and close to support, which is consistent with a weak tape rather than a confirmed bounce.
Intellectia Proprietary Trading Signals
on 2026-02-11 pre-market; any stabilization in subscription growth/NRR and clearer post-CEO-transition execution could re-rate the stock. Some analysts still carry positive ratings (e.g., Goldman Buy, Piper Overweight, Jefferies Buy), implying upside if execution stabilizes.
Event-driven negative overhang: management reduced FY25 revenue guidance for the second straight quarter (per analyst notes), which typically pressures multiples and sentiment until results stabilize. Insider activity is a major red flag: insiders are selling, with selling amount up ~627% over the last month. Quant/price-path stats provided also skew weak: similar-pattern analysis implies ~40% chance of -1.18% next day and -3.37% next week (near-term bias negative).
Latest reported quarter: 2025/Q3. Revenue grew to $192.1M (+12.72% YoY), but profitability weakened materially: net income fell to $4.0M (-43.98% YoY) and EPS to $0.02 (-50% YoY). Gross margin declined to 59.83% (-3.17% YoY). The mix (growth OK, margins/profits down) supports the market’s concern that the growth model is facing headwinds and/or higher costs, aligning with the recent guidance reductions.
Recent trend is clearly negative: multiple firms cut price targets sharply over 2025-11-03 to 2025-11-05 (e.g., Goldman $43→$28 while staying Buy; Piper $42→$32 Overweight; JMP $50→$37 Outperform; Jefferies $35→$28 Buy; several Holds/Neutrals cut into the low-to-mid $20s). Wall Street pros vs cons: Pros: some bullish firms argue demand drivers (SAP migration momentum, eInvoicing) remain intact and the stock may be at a trough multiple if stabilization occurs. Cons: repeated guidance cuts, net revenue retention pressure/churn commentary, execution risk (notably a December-weighted Q4), and expectations likely needing a reset—overall reducing confidence for an immediate buy.
